Brian Skorney
Stock Analyst at Baird
(3.42)
# 901
Out of 4,784 analysts
103
Total ratings
42.47%
Success rate
5.83%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Outperform | $72 → $102 | $71.99 | +41.69% | 3 | Mar 27, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $45.99 | +19.59% | 5 | Feb 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $940 → $759 | $637.36 | +19.08% | 13 | Feb 5, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $46 | $11.45 | +301.75% | 1 | Dec 13, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $13.43 | +123.38% | 1 | Dec 13, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.52 | +868.43% | 4 | Nov 29, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $26 → $20 | $5.71 | +250.26% | 6 | Nov 26, 2024 | |
| BIIB Biogen | Maintains: Outperform | $294 → $300 | $138.37 | +116.81% | 16 | Nov 15, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $200 → $193 | $70.41 | +174.11% | 9 | Nov 7, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $80 → $95 | $111.79 | -15.02% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $5.64 | +343.26% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $2.27 | +340.53% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $306.95 | -29.96% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $58 → $60 | $27.65 | +117.00% | 2 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $113.16 | +59.07% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $4.10 | +582.93% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $34.73 | +78.52% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $7.83 | +398.08% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $34.26 | +83.89% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $492.69 | -34.04% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $18.37 | -45.56% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.59 | +10,324.71% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.65 | +64.38% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $2.32 | +12,831.03% | 3 | May 7, 2018 | |
Soleno Therapeutics
Mar 27, 2025
Maintains: Outperform
Price Target: $72 → $102
Current: $71.99
Upside: +41.69%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $45.99
Upside: +19.59%
Regeneron Pharmaceuticals
Feb 5, 2025
Maintains: Neutral
Price Target: $940 → $759
Current: $637.36
Upside: +19.08%
Dyne Therapeutics
Dec 13, 2024
Initiates: Outperform
Price Target: $46
Current: $11.45
Upside: +301.75%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $13.43
Upside: +123.38%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.52
Upside: +868.43%
Enanta Pharmaceuticals
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $5.71
Upside: +250.26%
Biogen
Nov 15, 2024
Maintains: Outperform
Price Target: $294 → $300
Current: $138.37
Upside: +116.81%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $200 → $193
Current: $70.41
Upside: +174.11%
Gilead Sciences
Nov 7, 2024
Maintains: Neutral
Price Target: $80 → $95
Current: $111.79
Upside: -15.02%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $5.64
Upside: +343.26%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $2.27
Upside: +340.53%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $306.95
Upside: -29.96%
Sep 23, 2024
Maintains: Outperform
Price Target: $58 → $60
Current: $27.65
Upside: +117.00%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $113.16
Upside: +59.07%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $4.10
Upside: +582.93%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $34.73
Upside: +78.52%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $7.83
Upside: +398.08%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $34.26
Upside: +83.89%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $492.69
Upside: -34.04%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $18.37
Upside: -45.56%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.59
Upside: +10,324.71%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.65
Upside: +64.38%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $2.32
Upside: +12,831.03%